{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:40:13Z","timestamp":1793227213618,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373954"],"award-info":[{"award-number":["82373954"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173895"],"award-info":[{"award-number":["82173895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007625"],"award-info":[{"award-number":["INV-007625"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2705900"],"award-info":[{"award-number":["2023YFC2705900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01493-5","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T12:52:54Z","timestamp":1746449574000},"page":"885-898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir\/Ritonavir in HIV\/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease\u2013Drug\u2013Drug Interaction (DDDI)"],"prefix":"10.1007","volume":"64","author":[{"given":"Ling","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-8192","authenticated-orcid":false,"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"1493_CR1","unstructured":"WHO. HIV, Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission. 2021. https:\/\/www.whoint\/data\/gho\/data\/indicators\/indicator-details\/GHO\/estimated-percentage-of-pregnant-women-living-with-hiv-who-received-antiretrovirals-for-preventing-mother-to-child-transmission."},{"key":"1493_CR2","unstructured":"WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections. 2021. http:\/\/www.appswhoint\/iris\/bitstream\/handle\/10665\/342808\/9789240030985-engpdf."},{"issue":"19","key":"1493_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMp1201796","volume":"366","author":"AP Kourtis","year":"2012","unstructured":"Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection\u2013a global challenge. N Engl J Med. 2012;366(19):1749\u201352.","journal-title":"N Engl J Med"},{"key":"1493_CR4","unstructured":"NOoARAC. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. 2023. https:\/\/www.clinicalinfohivgov\/en\/guidelines\/perinatal\/whats-new."},{"key":"1493_CR5","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. https:\/\/www.whoint\/publications\/i\/item\/9789240031593."},{"key":"1493_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101368","volume":"46","author":"I Cowdell","year":"2022","unstructured":"Cowdell I, Beck K, Portwood C, Sexton H, Kumarendran M, Brandon Z, Kirtley S, Hemelaar J. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;46: 101368.","journal-title":"EClinicalMedicine"},{"key":"1493_CR7","unstructured":"Unitaid. Innovative agreement launches affordable, optimal second-line HIV treatment in low- and middle-income countries. 2021. https:\/\/www.unitaidorg\/news-blog\/innovative-agreement-affordable-optimal-second-line-hiv-treatment\/#en."},{"key":"1493_CR8","unstructured":"Registry A. The antiretroviral pregnancy registry interim report 1 January 1989 through 31 July 2023. Accessed 23 Jan 2024."},{"issue":"1","key":"1493_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/dmd.111.041400","volume":"40","author":"F Li","year":"2012","unstructured":"Li F, Lu J, Ma X. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos. 2012;40(1):18\u201324.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1493_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1208\/s12248-013-9505-3","volume":"15","author":"B Xia","year":"2013","unstructured":"Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013;15(4):1012\u201324.","journal-title":"AAPS J"},{"issue":"9","key":"1493_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1124\/dmd.120.000067","volume":"48","author":"O Anoshchenko","year":"2020","unstructured":"Anoshchenko O, Prasad B, Neradugomma NK, Wang J, Mao Q, Unadkat JD. Gestational age-dependent abundance of human placental transporters as determined by quantitative targeted proteomics. Drug Metab Dispos. 2020;48(9):735\u201341.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1493_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365\u201396.","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"1493_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2165\/00003088-200443150-00002","volume":"43","author":"M Mirochnick","year":"2004","unstructured":"Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1493_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/QAI.0b013e3181d6c9ed","volume":"54","author":"BM Best","year":"2010","unstructured":"Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54(4):381\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1493_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAI.0b013e318186edd0","volume":"49","author":"M Mirochnick","year":"2008","unstructured":"Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49(5):485\u201391.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1493_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40262-015-0325-8","volume":"55","author":"A Colbers","year":"2016","unstructured":"Colbers A, Greupink R, Litjens C, Burger D, Russel FG. Physiologically based modelling of darunavir\/ritonavir pharmacokinetics during pregnancy. Clin Pharmacokinet. 2016;55(3):381\u201396.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1493_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11095-014-1525-x","volume":"32","author":"T Yan","year":"2015","unstructured":"Yan T, Gao S, Peng X, Shi J, Xie C, Li Q, Lu L, Wang Y, Zhou F, Liu Z, Hu M. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS\/MS method. Pharm Res. 2015;32(3):1141\u201357.","journal-title":"Pharm Res"},{"key":"1493_CR18","unstructured":"FDA. Pregnant Women Scientific and Ethical Considerations for Inclusion in Clinical Trilals Guidance for Industry. Center for Drug Evaluation and Research April 2018, Clinical\/Medical Revision 1. https:\/\/www.fda.gov\/media\/112195\/download."},{"issue":"10","key":"1493_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"1493_CR20","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/QAD.0b013e32835584ea","volume":"26","author":"JB Nachega","year":"2012","unstructured":"Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;26(Suppl 1):S39-53.","journal-title":"AIDS"},{"issue":"9","key":"1493_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044793","volume":"7","author":"RA Murphy","year":"2012","unstructured":"Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS ONE. 2012;7(9): e44793.","journal-title":"PLoS ONE"},{"issue":"11","key":"1493_CR22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/infdis\/jiw439","volume":"214","author":"L Wang","year":"2016","unstructured":"Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, Liang S, Shepard C, Wang L, Wang A, Zhang F, Kourtis AP. Hepatitis B virus (HBV) load response to 2 antiviral regimens, tenofovir\/lamivudine and lamivudine, in HIV\/HBV-coinfected pregnant women in Guangxi, China: the tenofovir in pregnancy (TiP) study. J Infect Dis. 2016;214(11):1695\u20139.","journal-title":"J Infect Dis"},{"issue":"6","key":"1493_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/bdd.2243","volume":"41","author":"L Song","year":"2020","unstructured":"Song L, Yu Z, Xu Y, Li X, Liu X, Liu D, Zhou T. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Biopharm Drug Dispos. 2020;41(6):248\u201367.","journal-title":"Biopharm Drug Dispos"},{"key":"1493_CR24","unstructured":"FDA. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. https:\/\/www.fdagov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers."},{"issue":"10","key":"1493_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1124\/dmd.121.000538","volume":"49","author":"O Anoshchenko","year":"2021","unstructured":"Anoshchenko O, Storelli F, Unadkat JD. Successful prediction of human fetal exposure to p-glycoprotein substrate drugs using the proteomics-informed relative expression factor approach and PBPK modeling and simulation. Drug Metab Dispos. 2021;49(10):919\u201328.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1493_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/psp4.12674","volume":"10","author":"O Anoshchenko","year":"2021","unstructured":"Anoshchenko O, Milad MA, Unadkat JD. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome. CPT Pharmacometrics Syst Pharmacol. 2021;10(9):1057\u201370.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1493_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10928-017-9504-6","volume":"44","author":"E Haem","year":"2017","unstructured":"Haem E, Harling K, Ayatollahi SM, Zare N, Karlsson MO. Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2017;44(1):55\u201366.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1493_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","volume":"68","author":"A Schuch","year":"2019","unstructured":"Schuch A, Salimi Alizei E, Heim K, Wieland D, Kiraithe MM, Kemming J, Llewellyn-Lacey S, Sogukpinar \u00d6, Ni Y, Urban S, Zimmermann P, Nassal M, Emmerich F, Price DA, Bengsch B, Luxenburger H, Neumann-Haefelin C, Hofmann M, Thimme R. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut. 2019;68(5):905\u201315.","journal-title":"Gut"},{"issue":"2","key":"1493_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/hepr.12439","volume":"45","author":"M Isogawa","year":"2015","unstructured":"Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatol Res. 2015;45(2):179\u201389.","journal-title":"Hepatol Res"},{"issue":"9","key":"1493_CR30","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1128\/AAC.00100-07","volume":"51","author":"WT Jansen","year":"2007","unstructured":"Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother. 2007;51(9):3420\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1493_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","volume":"56","author":"A Dallmann","year":"2017","unstructured":"Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56(11):1303\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1493_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.dld.2013.06.004","volume":"45","author":"Y Niu","year":"2013","unstructured":"Niu Y, Wu Z, Shen Q, Song J, Luo Q, You H, Shi G, Qin W. Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis. 2013;45(12):1041\u20138.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1493_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1468-1293.2009.00767.x","volume":"11","author":"FT Aweeka","year":"2010","unstructured":"Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010;11(4):232\u20138.","journal-title":"HIV Med"},{"issue":"1","key":"1493_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/QAI.0b013e31827fd47e","volume":"63","author":"KB Patterson","year":"2013","unstructured":"Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr. 2013;63(1):51\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1493_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.721059","volume":"9","author":"S Zhao","year":"2021","unstructured":"Zhao S, Gockenbach M, Grimstein M, Sachs HC, Mirochnick M, Struble K, Belew Y, Wang J, Capparelli EV, Best BM, Johnson T, Momper JD, Maharaj AR. Characterization of plasma protein alterations in pregnant and postpartum individuals living with HIV to support physiologically-based pharmacokinetic model development. Front Pediatr. 2021;9: 721059.","journal-title":"Front Pediatr"},{"key":"1493_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ijid.2020.12.058","volume":"104","author":"FA Magaji","year":"2021","unstructured":"Magaji FA, Okolo MO, Yiltok ES, Golit W, Anzaku SA, Ogwuche J, Pam VC, Ocheke AN, Musa J, Isichie C, Imade GE, Mutihir JT, Ugwu BT, Agbaji O, Sagay SA, Zoakah AI, Cohn SE. Prevalence of hepatitis B virus infection in pregnant women with and without HIV in Jos, Nigeria. Int J Infect Dis. 2021;104:276\u201381.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1493_CR37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/cpt.2980","volume":"114","author":"J Dong","year":"2023","unstructured":"Dong J, Prieto Garcia L, Huang Y, Tang W, Lundahl A, Elebring M, Ahlstr\u00f6m C, Vildhede A, Sj\u00f6gren E, N\u00e5g\u00e5rd M. Understanding statin-roxadustat drug-drug-disease interaction using physiologically-based pharmacokinetic modeling. Clin Pharmacol Ther. 2023;114(4):825\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1493_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10557-021-07266-z","volume":"37","author":"Z Wang","year":"2023","unstructured":"Wang Z, Cheong EJY, Kojodjojo P, Chan ECY. Model-based risk prediction of rivaroxaban with amiodarone for moderate renal impaired elderly population. Cardiovasc Drugs Ther. 2023;37(3):605\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"1493_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","volume":"58","author":"K Abduljalil","year":"2019","unstructured":"Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet. 2019;58(2):235\u201362.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1493_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485\u2013505.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1493_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jbt.20179","volume":"21","author":"RN Hines","year":"2007","unstructured":"Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169\u201375.","journal-title":"J Biochem Mol Toxicol"},{"key":"1493_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.placenta.2020.07.009","volume":"100","author":"JF Robinson","year":"2020","unstructured":"Robinson JF, Hamilton EG, Lam J, Chen H, Woodruff TJ. Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues. Placenta. 2020;100:35\u201344.","journal-title":"Placenta"},{"issue":"2","key":"1493_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/B:JOPA.0000034404.86036.72","volume":"31","author":"J Ribbing","year":"2004","unstructured":"Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn. 2004;31(2):109\u201334.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01493-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:42:40Z","timestamp":1749649360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01493-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01493-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported by the National Natural Science Foundation of China (No. 82373954; 82173895); National Key Research and Development Program of China (2023YFC2705900). The Bill & Melinda Gates Foundation, Grant\/Award Number: INV-007625.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No authors reported potential conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data used in this study were collected in line with the principles of the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees for each study of which data was used in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All data generated or analysed during this study are included in this published article (and its supplementary information files).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"D.L. and L.S. conceived and designed the study. L.S. and G.X. developed and optimized current model work. J.S. and W.Y. analyzed the original data. L.S. prepared this manuscript. D.L. revised this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}